Abstract
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Reviews on Recent Clinical Trials
Title: Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Volume: 3 Issue: 3
Author(s): Stephan Kruck, Markus A. Kuczyk, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl and Axel S. Merseburger
Affiliation:
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Abstract: Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Export Options
About this article
Cite this article as:
Kruck Stephan, Kuczyk A. Markus, Gakis Georgios, Kramer W. Mario, Stenzl Arnulf and Merseburger S. Axel, Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700311
DOI https://dx.doi.org/10.2174/157488708785700311 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters Patent Selections
Recent Patents on Biomarkers A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Controlled Release of Plasmid DNA from Hyaluronan Nanoparticles
Current Drug Delivery Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs
Current Pharmaceutical Design Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design